Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Star Bulk Carriers Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Star Bulk Carriers Corp trades at $26.35 (market cap $2.94B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13.6× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 3.91% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SBLK | |
|---|---|---|
Market Cap | $39.89B | $2.94B |
Sector | Health | Industrials |
52-Week High | $491.22 | $28.21 |
52-Week Low | $278.09 | $16.79 |
Enterprise Value | $38.15B | $3.64B |
Dividend Yield | — | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Star Bulk Carriers (SBLK) trades at $26.35, up 1.82% today, with a neutral technical signal and bullish moving averages. The company reported strong Q1 2026 earnings of $0.56 per share, beating estimates, and maintains a dividend payout. Revenue grew to $1.1 billion in 2026, with net income margin improving to 13.01%. Analyst consensus is bullish with 14 buy ratings.
SBLK presents a positive outlook with earnings beats and dividend returns, but faces risks from dry bulk market volatility and economic cycles. The stock's valuation at a P/E of 21.08 is reasonable given growth, yet investor caution is warranted on global trade fluctuations impacting shipping demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
